Abstract:Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatiguability of skeletal muscles. It is an antibody-mediated disease, caused by autoantibodies targeting neuromuscular junction proteins. In the majority of patients (~85%) antibodies against the muscle acetylcholine receptor (AChR) are detected, while in 6% antibodies against the muscle-specific kinase (MuSK) are detected. In ~10% of MG patients no autoantibodies can be found with the classical diagnostics for AChR and MuSK antibodies (seronegative MG, SN-MG), making the improvement of methods for the detection of known autoantibodies or the discovery of novel antigenic targets imperative. Over the past years, using cell-based assays or improved highly sensitive immunoprecipitation assays, it has been possible to detect autoantibodies in previously SN-MG patients, including the identification of the low-density lipoprotein receptor-related protein 4 (LRP4) as a third MG autoantigen, as well as AChR and MuSK antibodies undetectable by conventional methods. Furthermore, antibodies against other extracellular or intracellular targets, such as titin, the ryanodine receptor, agrin, collagen Q, K<sub>v</sub>1.4 potassium channels and cortactin have been found in some MG patients, which can be useful biomarkers. In addition to the improvement of diagnosis, the identification of the patients' autoantibody specificity is important for their stratification into respective subgroups, which can differ in terms of clinical manifestations, prognosis and most importantly their response to therapies. The knowledge of the autoantibody profile of MG patients would allow for a therapeutic strategy tailored to their MG subgroup. This is becoming especially relevant as there is increasing progress toward the development of antigen-specific therapies, targeting only the specific autoantibodies or immune cells involved in the autoimmune response, such as antigen-specific immunoadsorption, which have shown promising results. We will herein review the advances made by us and others toward development of more sensitive detection methods and the identification of new antibody targets in MG, and discuss their significance in MG diagnosis and therapy. Overall, the development of novel autoantibody assays is aiding in the more accurate diagnosis and classification of MG patients, supporting the development of advanced therapeutics and ultimately the improvement of disease management and patient quality of life.

THE HUMAN ACETYLCHOLINE RECEPTOR ANTIBODY: STUDIES OF KINETIC AND BIOCHEMICAL PROPERTIES AND THE REACTION WITH ANTI‐IDIOTYPIC ANTIBODIES *

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Anti-presynaptic membrane receptor antibodies in myasthenia gravis.

Distribution and Temporal Changes of Autoantibody-Mediated Pathogenic Mechanisms Among Acetylcholine Receptor-Positive Myasthenia Gravis Patients

Chemoprophylaxis with diminazene aceturate in experimental Babesia bigemina infection in cattle.

The changing landscape of autoantibody testing in myasthenia gravis in the setting of novel drug treatments

Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms

Clinical significance of serum antibodies in different types of myasthenia gravis

Detection of Multiple Antibodies in Myasthenia Gravis and Its Clinical Significance

Advances of Serum Antibodies in Myasthenia Gravis

Myasthenia Gravis: T and B Cell Reactivities to the Β-Bungarotoxin Binding Protein Presynaptic Membrane Receptor

In-line affinity chromatographic removal of specific antibody from rabbits with experimental myasthenia gravis as a prelude to immunotherapy

Autoantibodies against M1 muscarinic acetylcholine receptor in myasthenic disorders

Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics

Stereotypic T cell receptor clonotypes in the thymus and peripheral blood of Myasthenia gravis patients

Exploring and Exploiting(?) the Awkward Connections Between SKOS and OWL

The Effect of CD3-specific Monoclonal Antibody on Treating Experimental Autoimmune Myasthenia Gravis.

Acetylcholinesterase inhibitors are ineffective in MuSK-antibody positive myasthenia gravis: Results of a study on 202 patients

Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?

Effects of Myasthenia Gravis Patients' Sera with Different Autoantibodies on Slow K+ Current at Mouse Motor Nerve Terminals

Diffusion tensor imaging for Alzheimer’s disease: A review of concepts and potential clinical applicability